Zydus Lifesciences inks licensing pact with Zhuhai for cancer drug

Zydus Lifesciences' subsidiary partners with Zhuhai Beihai Biotech to market Beizray, a cancer drug, in the US. Zhuhai will handle manufacturing while Zydus will commercialize the product, targeting breast cancer and other types. The partnership includes milestone payments and profit-sharing, tapping into a market of around 531,000 units annually.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AHKaUM6
via IFTTT